Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction

K. Takenaka, S. Yasuda, S. Miyazaki, T. Kurita, Y. Sutani, I. Morii, S. Daikoku, S. Kamakura, H. Nonogi

研究成果: ジャーナルへの寄稿学術論文査読

28 被引用数 (Scopus)

抄録

Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K+ channel blocker has therapeutic potential for acute myocardial infarction.

本文言語英語
ページ(範囲)60-62
ページ数3
ジャーナルJapanese Circulation Journal
65
1
DOI
出版ステータス出版済み - 2001

フィンガープリント

「Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル